I'm an inFLUencer of Change

Vaccine Medical Update Protection beyond Flu

Issue No. 2 MARCH 2024

Affairs of the Month

Understanding Protection Beyond Flu





Republic of the Philippines

Department of Health

Kagawaran ng Kalusugan

DOH CALENDAR CFI FBRATIONS

World Tuberculosis Day March 24

Publication Feature

Burden of Influenza among Tuberculosis patients

Is HD flu vaccine better?

Special Feature: WHO NH 2024-2025 Flu Strain is out!

MAT-PH-2400214 | Ver 1.0 | DA 03-2024 | DM 03-2024 This material is strictly for Healthcare Professionals only. Sanofi Pasteur, Inc

21st and 22nd Floors One World Place Corporate Offices 32nd Street, Taguig, Metro Manila

Affairs of the Month

Understanding Protection Beyond Flu

Influenza is a devastating and unpredictable disease. A new standard is required. Protection Beyond Flu is Sanofi's commitment to ensuring people have access to influenza vaccines with proven better protection against flu infection and its severe outcomes. Share these standards? Watch to find out more.

"Doing more to protect against influenza and its severe complications"

As we observe **World Tuberculosis Day on March 24**, it's important to acknowledge the gravity of having a coinfection. Studies have shown that individuals with both tuberculosis and influenza have a higher risk of mortality compared to those with either of the infections alone. Therefore, it's essential to be vigilant and take extra precautions to avoid contracting any illness that could exacerbate the risks of both tuberculosis and influenza. Let's work together to raise awareness about this issue and prevent the spread of these diseases.



Ref. Walaza S et al., Infect Dis. 2019 Mar 19;6(3):ofz020. doi: 10.1093/ofid/ofz020.

Publication Feature

Burden of Influenza among Tuberculosis Patients

Influenza and tuberculosis are deadly diseases that pose a significant threat to public health worldwide. Co-infection of influenza and TB can lead to chronic lung disease, immunosuppression, and death. It is crucial to prioritize vaccination efforts for those most at risk, including individuals with TB.

A recent study found that TB-infected individuals had a higher incidence of influenza A (H1N1)pdm09 than the general population. Policymakers should prioritize annual influenza vaccination for high-risk groups to reduce the risk of serious illness, hospitalization, and death.

By working together to prioritize vaccination efforts, we can safeguard public health and protect ourselves and others from the serious health risks associated with influenza and TB.

Click here to access the article

Ref: Umbreen, G., et al.BMC Infect Dis 23, 526 (2023). https://doi.org/10.1186/s12879-023-08441-3. Accessed February 26,2024

I'm an inFLUencer of Change

Vaccine Medical Update Protection beyond Flu

Issue No. 2 MARCH 2024

Affairs of the Month

Understanding Protection Beyond Flu



DOH CALENDAR CELEBRATIONS

World Tuberculosis Day March 24

Publication Feature

Burden of Influenza among Tuberculosis patients

Is HD flu vaccine better?

Special Feature:

WHO NH 2024-2025 Flu Strain is out!

MAT-PH-2400214 | Ver 1.0 | DA 03-2024 | DM 03-2024 This material is strictly for Healthcare Professionals only. Sanofi Pasteur, Inc

21st and 22nd Floors One World Place Corporate Offices 32nd Street, Taguig, Metro Manila

Publication Feature

Getting to know Sanofi's Improved Flu vaccines

Is the HIGH-DOSE flu vaccine better?

DANFLU -1: A pragmatic randomized feasibility trial of influenza vaccines

The High Dose (HD) influenza vaccine provides better protection against influenza infection than the SD influenza vaccine among adults aged 65 years and above. The DANFLU-1 trial has shown that it's possible to evaluate the rVE of QIV-HD versus QIV-SD in a real-world setting. QIV-HD is associated with lower rates of most clinical outcomes compared to QIV-SD, supporting the known clinical benefit of HD over SD. This individually randomized design provides high-quality evidence in a real-world setting and can be used to assess rVE in future seasons.

Click here to access the <u>publication</u>
<u>Click here to view the Interview with the investigator</u>
Ref: Johansen ND, et al. NEJM Evidence. 2023;2:EVIDoa2200206. DOI: 10.1056/EVIDoa2200206.

Special Feature

The World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season in the northern hemisphere.

The WHO recommends that quadrivalent vaccines for use in the 2023-2024 northern hemisphere influenza season contain the following:

Egg-based vaccines

- an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
- an A/Darwin/9/2021 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Ref: WHO News Recommendation for Influenza Vaccine Composition Northern Hemisphere 2024-2025 https://www.who.int/news/item/24-02-2023-recommendations-announced-for-influenza-vaccine-composition-for-the-2023-2024-northern-hemisphere-influenza-season. Accessed February 26,2024